vinorelbine tartrate / Generic mfg. 
Welcome,         Profile    Billing    Logout  

60 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
vinorelbine tartrate / Generic mfg.
2020-001938-35: AIRE: Investigation of the immune response after chemotherapy treatment with Eribulin: A trial for female patients with advanced breast cancer. AIRE: Untersuchung der Immunantwort nach Behandlung mit der Chemotherapie Eribulin: Eine Studie für Patientinnen mit fortgeschrittenem Brustkrebs.

Not yet recruiting
4
84
Europe
Eribulin, Paclitaxel, Paclitaxel Albumin-Bound, Capecitabine, Vinorelbine, Solution for injection, Concentrate for solution for infusion, Powder for solution for infusion, Tablet, Halaven, Paclitaxel, nab-Paclitaxel, Capecitabine, Vinorelbine
Institut für Frauengesundheit GmbH, Institut für Frauengesundheit (IFG) GmbH
Female patients diagnosed with HER2 negative advanced breast cancer, which had received at least one previous chemotherapy Patientinnen, die mit einem HER2 negativen Brustkrebs im fortgeschrittenem Stadium diagnostiziert wurden und zuvor mindestens eine Chemotherapie erhielten., Female patients which were diagnosed with advanced breast cancer. The tumor should not have a certain marker (HER2) on its surface (HER2 negative breast cancer). Patientinnen, die mit einem Brustkrebs im fortgeschrittenem Stadium diagnostiziert wurden. Den Tumorzellen fehlt ein bestimmter Marker (HER2) auf der Oberfläche (HER2-negativer Brustkrebs)., Diseases [C] - Cancer [C04]
 
 
NCT05131841: Cipterbin Combined With Vinorelbine in the Treatment of HER2-positive MBC

Recruiting
4
60
RoW
Cipterbin Combined With Vinorelbine
Zhejiang Cancer Hospital, Proswell Medical Corporation
Metastatic Breast Cancer
12/22
12/22
PADMA, NCT03355157 / 2016-004482-89: A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - Study).

Recruiting
4
150
Europe
Palbociclib / Chemotherapy (capecitabine, epirubicin, paclitaxel, vinorelbine) / Endocrine therapy (exemestane, fulvestrant, letrozole, tamoxifen)
German Breast Group, Pfizer, AMS Advanced Medical Services GmbH
Metastatic Breast Cancer
03/23
03/23
VIGOR, NCT05583188: Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC

Active, not recruiting
4
15
US
Aliya Pulsed Electric Fields (PEF) ablation, Nivolumab plus Platinum Doublet Chemotherapy, Carboplatinum, Cipsplatin, Pemetrexed, Gemcitabine, Paclitaxel, Standard of care neoadjuvant therapy, Vinorelbine, Surgical Resection
Galvanize Therapeutics, Inc.
NSCLC
06/24
06/24
2016-001063-36: Randomised phase III study testing nivolumab versus chemotherapy in first line treatment of PS 2 or elderly (more than 70 years old) patients with advanced non-small cell lung cancer Etude randomisée de phase III testant le nivolumab versus une chimiothérapie adaptée dans le traitement de première ligne du CBNPC chez des patients PS 2 ou de plus de 70 ans

Ongoing
3
242
Europe
nivolumab, carboplatin, pemetrexed, paclitaxel, gemcitabine, vinorelbine, Solution for infusion, Solution for injection, Powder for concentrate for solution for infusion, Powder for solution for infusion, Capsule, soft, OPDIVO
CHU Rennes, Bristol-Myers Squibb
Advanced non small cell lung cancer Cancer Bronchique Non à Petites Cellules avancé, Advanced non small cell lung cancer Cancer Bronchique Non à Petites Cellules avancé, Diseases [C] - Cancer [C04]
 
 
ARCTIC, NCT02352948 / 2014-000338-46: A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

Checkmark ARCTIC trial of durvalumab in combination with tremelimumab in PD-L1 negative NSCLC
Apr 2018 - Apr 2018: ARCTIC trial of durvalumab in combination with tremelimumab in PD-L1 negative NSCLC
Checkmark Completion of enrollment in P3 ARCTIC in durvalumab + tremelimumab for 3L NSCLC
Aug 2016 - Aug 2016: Completion of enrollment in P3 ARCTIC in durvalumab + tremelimumab for 3L NSCLC
Checkmark ARCTIC monotherapy trial for stage IIIB-IV NSCLC
More
Completed
3
597
Europe, Canada, Japan, US, RoW
MEDI4736 (durvalumab), Vinorelbine, Gemcitabine, Erlotinib, MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4), tremelimumab (anti-CTLA4)
AstraZeneca
Non - Small Cell Lung Cancer NSCLC
02/18
08/23
TULIP, NCT03262935 / 2017-001994-18: SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer

Completed
3
437
Europe, Canada, US, RoW
(vic-)trastuzumab duocarmazine, SYD985, Trastuzumab vc-seco-DUBA, Physician's choice, Lapatinib (Lap), Capecitabine (Cap), Trastuzumab (T), Vinorelbine (Vino), Eribulin (Eri)
Byondis B.V.
Metastatic Breast Cancer
03/21
06/22
CheckMate 816, NCT02998528 / 2016-003536-21: A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)

Hourglass Oct 2023 - Oct 2023 : Additional results (Abstract #1261O) from CheckMate -816 trial of neoadjuvant Opdivo in combination with Yervoy in resectable NSCLC at ESMO 2023
Checkmark Exploratory analyses from from CheckMate -816 trial in resectable NSCLC at ESMO 2022
Sep 2022 - Sep 2022: Exploratory analyses from from CheckMate -816 trial in resectable NSCLC at ESMO 2022
Checkmark EFS data from the P3 CheckMate -816 trial in NSCLC at AACR 2022
Apr 2022 - Apr 2022: EFS data from the P3 CheckMate -816 trial in NSCLC at AACR 2022
More
Active, not recruiting
3
505
Europe, Canada, Japan, US, RoW
Nivolumab, BMS-936558, Opdivo, Cisplatin, Vinorelbine, Gemcitabine, Docetaxel, Pemetrexed, Carboplatin, Paclitaxel, Ipilimumab, BMS-734016, Yervoy
Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd
Non Small Cell Lung Cancer
09/21
11/28
2021-002193-63: A Phase 3 Study of Balstilimab Compared to Chemotherapy Chosen by the Investigator in Cervical Cancer.

Not yet recruiting
3
486
Europe
Balstilimab, pemetrexed, Gemcitabine, irinotecan, Topotecan, Vinorelbine, AGEN2034, Solution for injection, Concentrate for solution for infusion, Solution for infusion, Powder for concentrate for solution for infusion, Pemetrexed Fresenius Kabi, Gemcitabine, Irinotecan, Topotecan, Vinorelbine
Agenus, Inc., Agenus, Inc.
recurrent, persistent, or metastatic cervical cancer that have progressed after receiving platinum-based chemotherapy, Cancer that develops in a woman's cervix, Diseases [C] - Cancer [C04]
 
 
R000007398: A randomized phase III trial of adjuvant gefitinib versus cisplatin and vinorelbine in completely resected (stage II-III) non-small cell lung cancer (NSCLC) patients with mutated EGFR (investigator-initiated multicenter clinical trial)

Completed
3
230
Japan
gefitinib - Generic mfg., cisplatin - Generic mfg., vinorelbine tartrate - Generic mfg.
Suita Tokushukai Hospital, AstraZeneca K.K.
Resected pathological stage II or III non-small cell lung cancer with mutated EGFR
 
 
2020-005620-12: A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Inoperable or Metastatic Hormone Receptor-positive, HER2-negative Breast Cancer Ensayo clínico de Dato-DXd en comparación con la quimioterapia de elección del investigador en cáncer de mama inoperable o metastásico, con receptores hormonales positivos HER2 negativo.

Not yet recruiting
3
700
Europe
Datopotamab deruxtecan, Eribulin mesylate, Capecitabine, Gemcitabine, Vinorelbine, DS-1062a, Powder for concentrate for solution for infusion, Solution for injection/infusion, Film-coated tablet, Powder for solution for infusion, HALAVEN, Capecitabine Accord, Bendacitabin, Bendarelbin
AstraZeneca AB, ASTRAZENECA AB, AstraZeneca AB
Inoperable or Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer that Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy Cáncer de mama inoperable o metastásico, con receptores hormonales positivos, HER2 negativo, tratado una o dos líneas previas de quimioterapia sistémica, Breast Cancer Cáncer de mama, Diseases [C] - Cancer [C04]
 
 
NCT06107790: Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of HS022 and Trastuzumab® in Combination With Vinorelbine Bitartrate Injection in the Treatment of HER2-positive Breast Cancer

Completed
3
570
RoW
HS022, Trastuzumab, Vinorelbine Bitartrate
Zhejiang Hisun Pharmaceutical Co. Ltd.
HER2-positive Breast Cancer
01/22
01/22
IPSOS, NCT03191786 / 2015-004105-16: A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy

Checkmark Presentation of data from IPSOS trial for Platinum-Ineligible NSCLC at ESMO 2022
Sep 2022 - Sep 2022: Presentation of data from IPSOS trial for Platinum-Ineligible NSCLC at ESMO 2022
Completed
3
453
Europe, Canada, RoW
Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, MPDL3280A, Vinorelbine, Navelbine®, Gemcitabine, Gemzar®
Hoffmann-La Roche
Non-Small Cell Lung Cancer
04/22
10/23
EVIDENCE, NCT02448797: Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutation

Active, not recruiting
3
320
RoW
Icotinib, Conmana, Chemotherapy, Navelbine, ALIMTA
Betta Pharmaceuticals Co., Ltd.
Non-small Cell Lung Cancer
06/22
12/23
RC48-C012, NCT04400695: A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2

Recruiting
3
366
RoW
RC48-ADC, RC48, Paclitaxel Injection, Taxol, Docetaxel Injection, Taxotere, Vinorelbine Tartrate Injection, Navelbine, Capecitabine Tablets, Xeloda
RemeGen Co., Ltd.
Breast Cancer
06/24
12/24
EVER-132-002, NCT04639986: Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)

Active, not recruiting
3
331
RoW
Sacituzumab Govitecan-hziy, IMMU-132, Trodelvy™, GS-0132, Eribulin Mesylate Injection, Halaven, Capecitabine Oral Product, Xeloda, Gemcitabine Injection, Gemzar, Vinorelbine injection, Navelbine
Gilead Sciences, Iqvia Pty Ltd, Medidata Solutions, Parexel
Metastatic Breast Cancer
12/25
12/25
NCT05134194: A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastatic Triple-negative Breast Cancer

Terminated
3
1
RoW
Camrelizumab、Capecitabine/eribulin/gemcitabine/vinorelbine, Capecitabine/eribulin/gemcitabine/vinorelbine
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Triple Negative Breast Cancer
01/22
12/22
innovaTV 301, NCT04697628 / 2019-001655-39: Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

Active, not recruiting
3
568
Europe, Canada, Japan, US, RoW
tisotumab vedotin, TIVDAK, topotecan, vinorelbine, gemcitabine, irinotecan, pemetrexed
Seagen Inc., Genmab
Cervical Cancer
07/23
08/25
NCT06143553: Paclitaxel Polymeric Micelles for Injection Versus TPC on the Treatment of HER2-negative Metastatic Breast Cancer (MBC).

Recruiting
3
168
RoW
Paclitaxel Polymeric Micelles for Injection, Eribulin Mesilate injection, Capecitabine Tablets, Gemcitabine Hydrochloride for Injection, Vinorelbine Tartrate Injection, Paclitaxel (albumin-bound)
Shanghai Yizhong Pharmaceutical Co., Ltd.
Metastatic Breast Cancer (MBC)
07/25
07/25
OptiTROP-Breast01, NCT05347134: SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

Active, not recruiting
3
254
RoW
SKB264, Eribulin, Capecitabine, Gemcitabine, Vinorelbine
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Triple Negative Breast Cancer
10/23
12/24
NCT06343948: A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer

Recruiting
3
382
RoW
BL-B01D1, Eribulin, Vinorelbine, Gemcitabine, Capecitabine
Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
HR+HER2- Breast Cancer
05/26
05/26
ALINA, NCT03456076 / 2017-004331-37: A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer

Active, not recruiting
3
257
Europe, Japan, US, RoW
Alectnib, RO5424802, Cisplatin, Vinorelbine, Navelbine, Gemcitabine, Gitrabin, Pemetrexed, Alimta®, Carboplatin
Hoffmann-La Roche
Carcinoma, Non-Small-Cell Lung
06/23
11/26
NCT06382142: A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

Not yet recruiting
3
436
RoW
BL-B01D1, Eribulin, Vinorelbine, Gemcitabine, Capecitabine
Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Triple-Negative Breast Cancer
05/26
05/26
NCT06383767: A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer

Not yet recruiting
3
378
RoW
ESG401, Eribulin, capecitabine, gemcitabine or vinorelbine (Treatment of Physician's Choice)
Shanghai Escugen Biotechnology Co., Ltd
Metastatic Breast Cancer
07/26
12/26
NCT06459180: A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

Not yet recruiting
3
686
NA
Sacituzumab Tirumotecan, MK-2870, Pemetrexed, Tisotumab Vedotin, Topotecan, Vinorelbine, Gemcitabine, Irinotecan
Merck Sharp & Dohme LLC, European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation
Cervical Cancer
10/28
10/28
JZP598-303, NCT06435429: A Phase 3, Randomized, Open-label, Controlled Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

Not yet recruiting
3
550
NA
Zanidatamab, Trastuzumab, Eribulin, Vinorelbine, Gemcitabine, Capecitabine
Jazz Pharmaceuticals
Metastatic HER2-positive Breast Cancer
04/31
04/31
IMpower010, NCT02486718 / 2014-003205-15: Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer []

Checkmark Data from IMpower010 trial for stage IB-IIIA NSCLC
Aug 2022 - Aug 2022: Data from IMpower010 trial for stage IB-IIIA NSCLC
Checkmark Results from IMpower010 trial in for adjuvant NSCLC at IASLC-WCLC
Aug 2022 - Aug 2022: Results from IMpower010 trial in for adjuvant NSCLC at IASLC-WCLC
Checkmark Approval for adjuvant NSCLC based on IMpower010
More
Active, not recruiting
3
1280
Europe, Canada, Japan, US, RoW
Atezolizumab, MPDL3280A; TECENTRIQ, Cisplatin, Vinorelbine, Docetaxel, Gemcitabine, Pemetrexed
Hoffmann-La Roche
Non-Small Cell Lung Cancer
01/24
08/35
NCT02344472 / 2014-002249-22: Detect V / CHEVENDO (Chemo vs. Endo)

Active, not recruiting
3
271
Europe
pertuzumab, Perjeta®, Trastuzumab, Herceptin®, Capecitabine, Paclitaxel, Vinorelbine, Docetaxel, Exemestane, Letrozole, Anastrozole, Fulvestrant, Ribociclib, Kisqali®, nab-Paclitaxel, eribulin, leuprorelin, goserelin
Prof. Wolfgang Janni, Roche Pharma AG, Novartis Pharmaceuticals, Eisai GmbH, Celgene Corporation
Metastatic Breast Cancer
01/25
01/25
TROPiCS-02, NCT03901339 / 2018-004201-33: Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer

Checkmark Data from TROPICS-02 trial for 3L+ HR+/HER2- metastatic breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Data from TROPICS-02 trial for 3L+ HR+/HER2- metastatic breast cancer at SABCS 2022
Checkmark Post hoc subgroup analysis from P3 TROPiCS-02 study in HR+ve, HER2-ve mBC at ESMO 2022
Sep 2022 - Sep 2022: Post hoc subgroup analysis from P3 TROPiCS-02 study in HR+ve, HER2-ve mBC at ESMO 2022
Checkmark Data from TROPICS-02 trial for 3L+ HR+/HER2- metastatic breast cancer at ESMO 2022
More
Completed
3
543
Europe, Canada, US
Sacituzumab Govitecan-hziy, IMMU-132, GS-0132, Eribulin, Capecitabine, Gemcitabine, Vinorelbine
Gilead Sciences
Metastatic Breast Cancer
10/23
10/23
JSKN003-302, NCT06079983: JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

Not yet recruiting
3
400
RoW
JSKN003, Capecitabine tablets, Gemcitabine hydrochloride for injection, Vinorelbine tartrate injection, Paclitaxel for injection (albumin-bound type), Docetaxel injection, Eribulin mesylate injection
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Breast Cancer
04/25
03/29
TROPION-Breast01, NCT05104866 / 2020-005620-12: A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy

Calendar Jan 2024 - Dec 2024: Data from TROPION-Breast01 trial for inoperable or metastatic HR+, HER2- breast cancer
Hourglass Feb 2024 - Mar 2024 : Q4 FY'23 - Acceptance of regulatory submission in US for 2-3L HR+, HER2- breast cancer (based on TROPION-Breast01 trial)
Active, not recruiting
3
732
Europe, Canada, Japan, US, RoW
Dato-DXd, Datopotamab deruxtecan (Dato-DXd, DS-1062a), Capecitabine, Gemcitabine, Eribulin, Eribulin Mesylate, Vinorelbine
AstraZeneca, Daiichi Sankyo
Breast Cancer
08/25
08/25
SYSA1501-007, NCT05901935: DP303c in Patients With HER2-positive Advanced Breast Cancer

Not yet recruiting
3
420
NA
DP303c, Trastuzumab, Vinorelbine Tartrate, Capecitabine tablets
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
HER2-positive Advanced Breast Cancer
01/26
07/28
ALPHABET, NCT05063786 / 2020-005639-65: Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer

Active, not recruiting
3
27
Europe
Trastuzumab, Herceptin, Alpelisib, Piqray, Fulvestrant, Faslodex, Vinorelbine, Navelbine, Capecitabine, Xeloda, Eribulin, Halaven
Spanish Breast Cancer Research Group, ETOP IBCSG Partners Foundation, Breast International Group, Novartis Pharmaceuticals
Advanced Breast Cancer
11/24
11/24
DUBHE-L-304, NCT05487391: A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.

Not yet recruiting
3
632
NA
QL1706 injection, Vinorelbine Tartrate, Paclitaxel, Cisplatin, Carboplatin, Pemetrexed, Placebo
Qilu Pharmaceutical Co., Ltd.
Carcinoma, Non-Small-Cell Lung
10/28
10/31
DATE study, jRCTs031190117: Phase II study of durvalumab (MEDI4736) maintenance therapy immediately after completion of chemoradiotherapy for unresectable locally advanced (stage III) non-small cell lung cancer (TORG1937/)

Completed
2
47
Japan
carboplatin - Generic mfg., cisplatin - Generic mfg., Teysuno (gimeracil/oteracil/tegafur) - Nordic Group, Otsuka, docetaxel - Generic mfg., paclitaxel - Generic mfg., vinorelbine tartrate - Generic mfg., Imfinzi (durvalumab) - AstraZeneca
Nippon Medical School Hospital, AstraZeneca
Untreated locally advanced stage III NSCLC
 
 
RELIANCE, jRCTs071230065: LOGIK2301() (LOGIK2301())

Recruiting
2
33
Japan
cisplatin - Generic mfg., vinorelbine tartrate - Generic mfg., Tecentriq (atezolizumab) - Roche
Kitakyushu Municipal Medical Center, Chugai Pharmaceutical Co., Ltd.
Non-small cell lung cancer
 
 
2018-003719-23: An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants with Minimal Residual Disease After Surgical Removal

Not yet recruiting
2
340
Europe, RoW
NIVOLUMAB-10ml vial-COMMERCIAL, Vinorelbine, Gemcitabine, Gemcitabine Powder for Solution for Infusion, Docetaxel, Alimta (Pemetrexed), Cisplatin, Carboplatin, Paclitaxel, BMS-936558, L01BC05, Concentrate for solution for infusion, Powder for solution for infusion, Powder for concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion., Vinorelbine NC 10 mg/ml – Concentrate for preparing a solution for infusion, Vinorelbin Aurobindo 10 mg/ml Concentrate for Solution for Infusion, GEMCI-cell 38 mg/ml Concentrate for solution for infusion, Gemcitabine 1 g Powder for Solution for Infusion, Docetaxel Hospira 10 mg/ml Concentrate for Solution for Infusion, Alimta, Cisplatin NeoCorp 1 mg/ml - Concentrate for solution for infusion, Cisplatin-Ebewe, 1 mg/ml concentrate for solution for infusion, Cisplatin Teva® 1 mg/ml concentrate for solution for infusion, Carboplatin Aurobindo 10 mg/ml concentrate for solution for infusion, BENDATAX 6 mg/ml Concentrate for solution for Infusion, Paclitaxel Aurobindo 6 mg/ml concentrate for solution for infusion, Paclitaxel-GRY 6 mg/ml concentrate for solution for infusion, Docetaxel Ebewe 10 mg/ml concentrate for solution for infusion, Doce NC® 10 mg/ml concentrate for solution for infusion, Navirel® 10 mg/mL
Bristol-Myers Squibb International Corporation, Bristol-Myers Squibb International Corporation
Non-Small Cell Lung Cancer with ctDNA detected Minimal Residual Disease after Surgical Resection, Lung Cancer with minimal residual disease detected after surgery, Diseases [C] - Cancer [C04]
 
 
NCT04262804: A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC

Active, not recruiting
2
123
RoW
Margetuximab, Trastuzumab, Chosen Chemotherapy (Capecitabine), Chosen Chemotherapy (Vinorelbine ), Chosen Chemotherapy (Gemcitabine )
Zai Lab (Shanghai) Co., Ltd.
Breast Cancer Metastatic
09/21
12/23
RIGHT Choice, NCT03839823: Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer

Completed
2
223
RoW
Docetaxel / Capecitabine, Combination chemotherapy group., The chemotherapy regimen will be decided by the treating physician., Capecitabine / Vinorelbine, Paclitaxel / Gemcitabine, Ribociclib, Endocrine treatment arm:, NSAI + goserelin+ ribociclib, Letrozole OR Anastrozole, Goserelin
Novartis Pharmaceuticals
Breast Cancer
04/22
05/23
2021-002561-18: Single arm phase II study of the efficacy and safety of the combination of Trastuzumab plus TUCAtinib plus viNorelbine in patients with HER2-positive non-resectable locally advanced or metastatic breast cancer “TrasTUCAN Study” Estudio fase 2 de un solo brazo sobre la eficacia y la seguridad de la combinación de trastuzumab, TUCAtinib y viNorelbina en pacientes con cáncer de mama localmente avanzado no resecable o metastásico HER2-positivo «Estudio TrasTUCAN

Ongoing
2
49
Europe
Film-coated tablet, TUKYSA
GEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama), SEAGEN Inc
Non-resectable locally advanced or metastatic HER2-positive breast cancer. Cáncer de mama irresecable localmente avanzado o metastásico HER2-positivo., Non-resectable locally advanced or metastatic HER2-positive breast cancer. Cáncer de mama irresecable localmente avanzado o metastásico HER2-positivo., Diseases [C] - Cancer [C04]
 
 
SAFIR02_Breast, NCT02299999: - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer

Active, not recruiting
2
1460
Europe
AZD2014, AZD4547, AZD5363, AZD8931, Selumetinib, ARRY-142866, Vandetanib, CAPRELSA, Bicalutamide, Casodex, Olaparib, Lynparza, Anthracyclines, Doxorubicin, Epirubicin, liposomal doxorubicin, Taxanes, paclitaxel, docetaxel, cyclophosphamide, Novatrex, Imeth, DNA intercalators, capecitabine, 5-FU, gemcitabine, Methotrexate, vinca alkaloids, vinorelbine, vinblastine, vincristine, Platinum based chemotherapies, Platinum, carboplatin, cisplatin, Bevacizumab, Avastin, Mitomycin C, Ametycine, Eribulin, Halaven, MEDI4736
UNICANCER, Fondation ARC, AstraZeneca
Metastatic Breast Cancer
12/22
12/24
DURATION, NCT03345810 / 2016-003963-20: Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC

Completed
2
200
Europe
Durvalumab, MEDI4736, Vinorelbine, Gemcitabine, nab-Paclitaxel, Abraxane, Carboplatin
AIO-Studien-gGmbH, AstraZeneca, Celgene
Carcinoma, Non-Small-Cell Lung, Metastatic Lung Cancer, Non Small Cell Lung Cancer, Lung Adenocarcinoma Metastatic, Large Cell Lung Carcinoma Metastatic
12/22
12/22
2022-002582-15: Phase II Study mit Neratinib and Trastuzumab with or without Vinorelbine per mouth in patients with pretreated metastatic Her2- positive breast cancer Phase II Study mit Neratinib and Trastuzumab with or without Vinorelbine per mouth in patients with pretreated metastatic Her2- positive breast cancer

Ongoing
2
65
Europe
Neratinib, Navelbine, PRD7433212, L01CA04, Film-coated tablet, Capsule, Nerlynx, Navelbine
Medical University Graz, Pierre Fabre
Patients with histologically confirmed Human Epidermal Growth Factor Receptor 2 (HER2)-positive metastatic breast cancer (mBC) pretreated with trastuzumab, pertuzumab, and/or trastuzumab emtansine (T-DM1) and/ or T-DXd and/or tucatinib Patientinnen mit histologisch bestätigten Human Epidermen Wachstumsfaktor Rezeptor 2 (Her2) positiven metasierten Brustkrebserkrankung, vorbehandelt mit Trastuzumab, Pertuzumab und/ oder Trastuzumab Emtansine (T-DM1) und/ oder Trastuzumab Deruxtecan und/ oder Tucatinib, Patients with Her2 positive metastatic breast cancer who were pretreted with 2-4 lines of previous treatment Patientinnen mit Her2 positiven metastasierten Brustkrebserkrankung die mit 2-4 Therapielinien vorbehandelt wurden, Diseases [C] - Cancer [C04]
 
 
AVIATOR, NCT03414658: The Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer

Hourglass Mar 2019 - Dec 2019 : From trial for cancer (unspecified)
Active, not recruiting
2
100
US
Vinorelbine, Trastuzumab, Avelumab, Utomilumab
Adrienne G. Waks, Pfizer, Breast Cancer Research Foundation, Johns Hopkins University
Breast Cancer
05/23
05/25
ATREZZO, NCT04759248 / 2020-000245-13: Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer

Recruiting
2
55
Europe
Atezolizumab + Trastuzumab + Vinorelbine
SOLTI Breast Cancer Research Group, Roche Pharma AG
Breast Cancer
12/24
01/25
MCLA-128-CL02, NCT03321981 / 2017-002821-39: MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

Completed
2
105
Europe, US
Zenocutuzumab, MCLA-128, Trastuzumab, Herceptin, Vinorelbine, Navelbine, vinorelbine tartrate, Endocrine therapy, fulvestrant, exemestane, letrozole, anastrazole
Merus N.V.
Breast Cancer Metastatic
10/22
07/23
NCT06377566: A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

Recruiting
2
71
US
Brentuximab vedotin, Doxorubicin, Vinblastine, Dacarbazine, Pembrolizumab, Gemcitabine, Vinorelbine, FDG-PET/CT scan
Memorial Sloan Kettering Cancer Center, Seagen Inc.
Hodgkin Lymphoma
04/27
04/27
NCT03618550: Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

Recruiting
2
69
US
pembrolizumab, gemcitabine, vinorelbine, liposomal doxorubicin, Stem cell mobilization and collection
Memorial Sloan Kettering Cancer Center, Merck Sharp & Dohme LLC
Hodgkin Lymphoma, Relapsed or Refractory Hodgkin Lymphoma
08/24
08/24
CAMPFIRE, NCT05999994: A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer

Recruiting
2
105
Europe, Japan, US, RoW
Ramucirumab, LY3009806, Cyclophosphamide, Vinorelbine, Gemcitabine, LY188011, Docetaxel, Abemaciclib, LY2835219, Irinotecan, Temozolomide
Eli Lilly and Company
Neoplasms, Child, Adolescent
05/26
05/26
BRIDGE, NCT04765709: Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC

Active, not recruiting
2
10
Europe
durvalumab plus platinum-based chemotherapy (cisplatin or carboplatin plus vinorelbine or pemetrexed), Durvalumab plus radiotherapy, durvalumab
Mario Negri Institute for Pharmacological Research, AstraZeneca, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Non-small Cell Lung Cancer Stage III
06/26
06/26
TrasTUCAN, NCT05583110 / 2021-002561-18: Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer

Recruiting
2
49
Europe
Tucatinib, Tukysa, Trastuzumab, Herceptin, Vinorelbine, Navelbine
Spanish Breast Cancer Research Group, Seagen Inc.
HER2-positive Metastatic Breast Cancer, Locally Advanced HER2 Positive Breast Carcinoma
08/26
08/26
NCT06202261: A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer

Recruiting
1/2
154
RoW
TQB2930 for injection, Paclitaxel for injection (albumin-bound), TQB3616 capsule, Fulvestrant injection, Capecitabine tablets, Vinorelbine tartrate injection, Eribulin mesylate injection, gemcitabine hydrochloride for injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Metastatic Breast Cancer, Recurrent Breast Cancer, Advanced Malignancies
12/26
10/27
2019-101826, NCT04896320: Tucatinib With Chemotherapy and Trastuzumab in Advanced Her-2-neu Overexpressing, Previously Treated Breast Cancer.

Withdrawn
1/2
40
US
Tucatinib
Providence Health & Services, Seagen Inc.
Breast Cancer Stage IV
06/23
06/23
NCT04145349 / 2018-004242-42: CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor

Active, not recruiting
1/2
34
Europe, Japan, US, RoW
Ramucirumab, LY3009806, Cyclophosphamide, Vinorelbine
Eli Lilly and Company
Desmoplastic Small Round Cell Tumor
06/24
10/24
FIL_A-BEGEV, NCT05300282: Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients

Recruiting
1/2
140
Europe
Atezolizumab, BEGEV, Bendamustine, Gemcitabine, Vinorelbine
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Relapsed or Refractory Hodgkin's Lymphoma
05/25
12/28
NCT05299164: GVM±R in Patients With Relapsed or Refractory Aggressive NHL

Active, not recruiting
1
18
RoW
Liposomal Mitoxantrone Hydrochloride dose level 1, Liposomal Mitoxantrone Hydrochloride dose level 2, Liposomal Mitoxantrone Hydrochloride dose level 3, Liposomal Mitoxantrone Hydrochloride dose level 4
Institute of Hematology & Blood Diseases Hospital, China, CSPC Ouyi Pharmaceutical Co., Ltd.
Non Hodgkin Lymphoma
12/23
12/25
NCT04299113: Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma

Recruiting
1
38
US
Vinorelbine, 3'',4''-Didehydro-4''-deoxy-C''-norvincaleukoblastine, 5''-Nor-Anhydrovinblastine, 71486-22-1, Dihydroxydeoxynorvinkaleukoblastine, nor-5''-Anhydrovinblastine, vinorelbine, VINORELBINE, Mocetinostat, 726169-73-9, Benzamide, N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]-, MG-0103, MGCD0103, MGCD0103, N-(2-aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide
Jonsson Comprehensive Cancer Center, Mirati Therapeutics Inc., Phase One Foundation
Rhabdomyosarcoma
05/25
05/26
ZWI-ZW25-101, NCT02892123: Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers

Active, not recruiting
1
279
Canada, US, RoW
ZW25 (Zanidatamab), Paclitaxel, Capecitabine, Vinorelbine, Tucatinib
Jazz Pharmaceuticals
HER2-expressing Cancers
06/24
07/24
ACT, NCT05238831: SMMART Adaptive Clinical Treatment () Trial

Withdrawn
1
25
NA
Alectinib, AF-802, AF802, Alecensa, ALK Inhibitor RO5424802, CH5424802, RG7853, RO5424802, Alpelisib, BYL719, Phosphoinositide 3-kinase Inhibitor BYL719, Piqray, VIJOICE, Anastrozole, Anastrazole, Arimidex, ICI D1033, ICI-D1033, ZD-1033, Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Zirabev, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Capecitabine, Ro 09-1978/000, Xeloda, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cobimetinib, Cotellic, GDC-0973, MEK Inhibitor GDC-0973, XL518, Entrectinib, Rozlytrek, RXDX 101, RXDX-101, RXDX101, Eribulin, ER-086526, Fulvestrant, Faslodex, Faslodex(ICI 182,780), ICI 182,780, ICI 182780, ZD9238, Hyaluronidase-zzxf/Pertuzumab/Trastuzumab, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf, Pertuzumab/Trastuzumab/Hyaluronidase-zzxf, Phesgo, Irinotecan, Letrozole, CGS 20267, Femara, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, Protein-bound Paclitaxel, Niraparib, MK-4827, MK4827, Olaparib, AZD 2281, AZD-2281, AZD2281, KU-0059436, Lynparza, PARP Inhibitor AZD2281, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Palbociclib, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, Ibrance, PD 0332991, PD 332991, PD 991, PD-0332991, Pertuzumab, 2C4, 2C4 Antibody, EG1206A, HLX11, HS627, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, Perjeta, Pertuzumab Biosimilar EG1206A, Pertuzumab Biosimilar HLX11, Pertuzumab Biosimilar HS627, rhuMAb2C4, RO4368451, Quality-of-Life Assessment, Quality of Life Assessment, Trastuzumab, ABP 980, ALT02, Anti-c-ERB-2, Anti-c-erbB2 Monoclonal Antibody, Anti-ERB-2, Anti-erbB-2, Anti-erbB2 Monoclonal Antibody, Anti-HER2/c-erbB2 Monoclonal Antibody, Anti-p185-HER2, c-erb-2 Monoclonal Antibody, HER2 Monoclonal Antibody, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Herzuma, Kanjinti, MoAb HER2, Monoclonal Antibody c-erb-2, Monoclonal Antibody HER2, Ogivri, Ontruzant, PF-05280014, QL 1701, QL-1701, QL1701, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar QL1701, Trastuzumab Biosimilar SB3, Trastuzumab Biosimilar SIBP-01, Trastuzumab-anns, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-pkrb, Trastuzumab-qyyp, Trazimera, Trastuzumab Emtansine, Ado Trastuzumab Emtansine, ADO-Trastuzumab Emtansine, Kadcyla, PRO132365, RO5304020, T-DM1, Trastuzumab-DM1, Trastuzumab-MCC-DM1, Trastuzumab-MCC-DM1 Antibody-Drug Conjugate, Trastuzumab-MCC-DM1 Immunoconjugate, Vemurafenib, BRAF (V600E) kinase inhibitor RO5185426, BRAF(V600E) Kinase Inhibitor RO5185426, PLX-4032, PLX4032, RG 7204, RG7204, RO 5185426, Zelboraf, Vinorelbine, Dihydroxydeoxynorvinkaleukoblastine, Vismodegib, Erivedge, GDC-0449, Hedgehog Antagonist GDC-0449
OHSU Knight Cancer Institute, Genentech, Inc., Oregon Health and Science University
Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma, Advanced Prostate Carcinoma, Advanced Sarcoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Recurrent Adult Soft Tissue Sarcoma, Recurrent Breast Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Prostate Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
05/26
05/26
NCT02985658: Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer

No Longer Available
N/A
US
Veliparib, ABT-888, Cisplatin, Platinol-AQ, Platinol, Vinorelbine, Navelbine
University of Washington, AbbVie
Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation, Triple-Negative Breast Cancer
 
 

Download Options